China NT Pharma : Supplemental Agreement in Relation to Proposed Issuance of Convertible Preference Shares

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011) SUPPLEMENTAL AGREEMENT IN RELATION TO PROPOSED ISSUANCE OF CONVERTIBLE PREFERENCE SHARES

Reference is made to the announcement of the Company dated 19 April 2017 (the "Announcement") in relation to, among other things, the proposed issuance of Convertible Preference Shares. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

SUPPLEMENTAL AGREEMENT

On 21 April 2017 the Company entered into a supplemental agreement (the "Supplemental Agreement") with the Placing Agent to clarify the dividend arrangement in relation to the holders of Convertible Preference Shares.

Pursuant to the Supplemental Agreement, holders of the Convertible Preference Shares are not entitled to the final dividend for the year ended 31 December 2016 (details of which are set out in the annual result announcement of the Company dated 21 March 2017).

Save for the inclusion of the above clarification, all other terms of the Placing Agreement and terms of the Convertible Preference Shares remain unchanged.

Completion of the Placing is subject to the satisfaction of conditions precedent of the Placing Agreement (as amended by the Supplemental Agreement). As the Placing may or may not proceed, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

China NT Pharma Group Company Limited Ng Tit

Chairman

Hong Kong, 21 April 2017

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Directors of the Company are Dr. Qian Wei and Mr. Ge Jianqiu; and the independent non-executive Directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.